Cystinuria subtype and the risk of nephrolithiasis11See Editorial by Chesney, p. 279  by Goodyer, Paul et al.
Cystinuria subtype and the risk of nephrolithiasis1
PAUL GOODYER, IRFAN SAADI, PATRICIA ONG, GAY ELKAS, and RIMA ROZEN
Departments of Pediatrics, Human Genetics, Experimental Medicine, and Biology, McGill University, Montreal Children’s Hospital,
Montreal, Quebec, Canada
Cystinuria subtype and the risk of nephrolithiasis.
Background. Cystinuria patients may be classified into several subgroups
based on the urinary phenotype of heterozygotes. However, the relative
risk for nephrolithiasis and the prevalence of SLC3A1 mutations in these
subgroups are unknown.
Methods. Urinary cystine excretion, age at onset of nephrolithiasis and
nature of SLC3A1 mutations were assessed prospectively in 23 cystinuria
patients identified primarily through the Quebec Newborn Screening
Program. Probands were classified as to cystinuria subtype on the basis of
parental urinary cystine excretion.
Results. For classical Type I/I cystinuria, both parents excrete cystine in
the normal range and probands carry two mutations of the SLC3A1 gene
in nearly every case. Between ages 1 to 7 years, mean cystine excretion was
high (4566 6 480 mmol cystine/g creatinine) and exceeded the theoretic
threshold for solubility on 70% of visits. Four of eight Type I/I patients
began forming stones in the first decade. Type I/III patients (N 5 12)
excreted less cystine (1544 6 163 mmol cystine/g creatinine), exceeded the
threshold of urinary cystine solubility less frequently (22% of visits) and
had no nephrolithiasis in the first decade; one formed a stone at age 16
years. Only one SLC3A1 mutation was identified in this group. Two Type
II/N cystinuria children were identified. In these families, the same level of
relatively high excretion (.600 mmol cystine/g creatinine) was noted in
two or three generations, but no SLC3A1 mutations were identified.
Conclusions. Classical recessive Type I/I cystinuria is genetically and
phenotypically distinct from the other subtypes (Type I/III and Type II/N)
identified in our population.
Cystinuria is an inherited defect in the reabsorptive
transport of cystine and the dibasic amino acids (ornithine,
arginine and lysine) from the luminal fluid of the renal
proximal tubule and small intestine. Among affected pa-
tients, nephrolithiasis occurs when urinary cystine exceeds
its solubility at low pH. Certain individuals may develop
massive staghorn calculi in the pediatric years, while others
may form their first stone only in the second or third decade
of life. Classically, at least three cystinuria subtypes have
been recognized, based on the level of urinary cystine in
obligate heterozygotes [1]. The heterozygous parents of our
patients were classified as follows: (a)
Type I/Normal, urine cystine 5 0 to 100 mmol/g creati-
nine; (b) Type III/Normal, urine cystine 5 100 to 600
mmol/g creatinine; (c) Type II/Normal, urine cystine 5
990-1740 mmol/g creatinine.
Heterozygotes within a family tend to excrete cystine in
the same range, but for Type I/Normal and Type III/
Normal heterozygotes, this is not usually high enough to
put them at risk for stone formation. Offspring who inherit
two mutant cystinuria genes excrete much higher levels of
cystine (1,000 to 8,000 mmol cystine/g creatinine)–ap-
proaching the filtered load–and this may exceed the thresh-
old of cystine solubility as urine is concentrated and
acidified in the renal collecting tubules. Since patients
usually come to medical attention only after they have
formed stones, the incidence of nephrolithiasis among
cystinuria patients is not known. Furthermore, it is unclear
whether the risk of nephrolithiasis in these patients is
linked to their genotype.
Initially it was postulated that the variation among
cystinuria subtypes would be explained by mild, moderate
or severe mutations at a single chromosomal locus. How-
ever, we noted that affected children born of two parents
excreting cystine in the normal range (Type I/Normal) had
significantly higher urinary cystine than children born of
matings in which one parent excreted cystine in the normal
range (Type I/Normal), while the other had moderately
elevated cystine (Type III/Normal) [2]. We speculated that
this might be explained by genetic complementation be-
tween two distinct cystinuria loci [2].
In 1993, a human cDNA was isolated that induced
uptake of cystine, dibasic and some neutral amino acids
when expressed in Xenopus laevis oocytes [3, 4]. The gene,
SLC3A1 (D2H or rBAT), was mapped by somatic cell
hybridization [3, 4] and FISH analysis [5] to a region of
chromosome band 2p21 containing the cystinuria locus as
determined by linkage analysis [6]. Subsequently, over 20
different mutations of SLC3A1 have been identified in
cystinuria families from Italy/Spain [7–9], Israel/USA [10],
Japan [11] and Canada [12], and all mutations reported to
date have been associated with chromosomes linked to
Type I cystinuria. It has now been shown that Type III and
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probably Type II cystinuria are linked to a second cystinuria
locus at chromosome 19q13.1 [13–15].
In this report, we describe long-term clinical follow-up
studies of a cohort of cystinuria patients who were identi-
fied primarily via the Quebec Network of Genetic Medicine
Neonatal Screening Program. The patients were classified
as to cystinuria subtype on the basis of parental urinary
phenotype as previously reported [2, 12] and by analysis of
SLC3A1 gene mutations. Our studies suggest that Type I/I
cystinuria patients have the highest risk for nephrolithiasis.
METHODS
The Quebec Network of Genetic Medicine maintains a
urinary screening program for several heritable diseases,
and infants with elevated excretion of cystine are identified
and referred to tertiary centers for follow-up. Since some
infants with heterozygous cystinuria excrete cystine and
dibasic acids in the “homozygous” range during the first
months of life, a final diagnosis of cystinuria is made at one
year of age when maturation of normal cystine reabsorptive
transport can be expected [16]. After exclusion of general-
ized Fanconi syndrome and other diseases, cystinuria pro-
bands excreting more than 1000 mmol cystine per gram
creatinine are referred to a tertiary care center, such as the
Renal-Genetics Clinic at the Montreal Children’s Hospital,
for investigation.
Fresh urine samples were obtained from parents and
siblings referred to our clinic. Urinary cystine, ornithine,
arginine and lysine were quantified by elution chromatog-
raphy on ion-exchange resin columns with a Beckman 6300
amino acid analyzer (Beckman Instruments, Mississauga,
Ontario, Canada). Urinary phenotype was assigned for
parents according to the cystinuria subtype classification
above [2], and the proband subtype was then assigned
accordingly. Nine Type I/I probands, 12 Type I/III pro-
bands, and two Type II/N probands were followed for 6 to
30 years. Average urinary cystine excretion (mmol cystine
per gram creatinine) was calculated from 4 to 12 random
morning samples collected during routine visits to the clinic
between the ages of one and seven years. These samples
were also used to plot cystine concentration (mmol cystine/
liter) versus urinary pH in relation to the curve describing
theoretic cystine solubility. In the subset of children who
formed cystine stones, successive urine samples were col-
lected throughout the day; cystine concentration was plot-
ted versus pH for each sample. Renal ultrasonography was
performed routinely every one to three years or as needed
to identify nephrolithiasis. One child, who was diagnosed
elsewhere, did not have multiple urine samples analyzed
during the first seven years of life. He was classified on the
basis of molecular analyses and included only for the
purpose of defining risk of nephrolithiasis in the first
decade. For all children, parents were instructed to main-
tain high fluid intake, but none were treated with mercap-
topropionyl glycine or penicillamine prior to onset of
recurrent stones.
DNA was isolated from peripheral lymphocytes with
informed consent [12]. To detect large deletions or gene
rearrangements, 5 mg of DNA was digested with appropri-
ate restriction enzymes and analyzed on Southern blots
using a radiolabeled SLC3A1 cDNA probe as previously
described [12]. Genomic DNA was also amplified by PCR,
using primers for each SLC3A1 exon plus flanking splice
junctions [12]. Heteroduplex analysis of PCR products was
used to detect small insertions or deletions; SSCP analysis
of radioactive PCR products was used for detection of base
substitutions [12]. Following the identification of heterodu-
plexes or abnormally migrating bands on SSCP gels, PCR
products were sequenced. Confirmation of sequence
changes was performed by a new PCR with restriction
analysis if the mutation created or obliterated a restriction
site. When a naturally occurring restriction site was unavail-
able, restriction sites were artificially created during the
PCR.
RESULTS
Type I/I cystinuria
Among the eight probands classified as Type I/I on the
basis of parental phenotype, we identified two mutations of
the SLC3A1 gene in seven of the eight patients (Table 1).
In the eight patient, only one mutation was found. Since
two of the probands were siblings, this represents a detec-
tion rate of 93% (13 mutations identified among 14 unre-
lated alleles). A ninth patient (#1440-1 referred at age 30)
was homozygous for an SLC3A1 mutation, but parents
were unavailable for urinary phenotyping. Detailed molec-
ular analyses of the SLC3A1 mutations in our population
are described in the accompanying manuscript [17].
Multiple random morning urine samples (N 5 4 to 12)
were available from seven of the nine Type I/I patients
between the ages of one to seven years (data was available
only after age 7 for one patient and only 3 values were
available for another). The mean cystine excretion for the
group was 4566 6 480 (SEM) mmol cystine/g creatinine for
the group; the mean and 95% confidence intervals for each
individual are listed in Table 1. When the cystine concen-
tration was plotted against urinary pH over the same time
period, 70% of samples were found to exceed the theoretic
limit of cystine solubility in aqueous solution (Fig. 1).
Four of the eight Type I/I patients followed prospectively
formed kidney stones in the first decade of life. Of the four
children who have not yet formed a kidney stone, three are
still less than 10 years of age and were started on potassium
citrate therapy between six and seven years of age because
of consistent cystine excretion in the supersaturated range.
All stones were associated with episodes of abdominal pain
and mild microscopic hematuria, and were confirmed by
renal ultrasonography or radiography.
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Four of the children who formed stones in the first
decade of life and one stone-free sibling were asked to
provide successive urine samples during two 24-hour peri-
ods. Urine samples were clustered into early morning (5 to
7 a.m.), noontime (11 a.m. to 12 p.m.), afternoon (3 to
4 p.m.) and evening (8 to 10 p.m.) samples, and plotted
versus urine pH in relation to the theoretic cystine solubil-
ity curve (Fig. 2). In each case, cystine concentration
exceeded the theoretic limit of cystine solubility to the
greatest degree in early morning (8 of 8) or late evening (4
of 5) samples. During the day, urine cystine concentration
tended to be below or just above the solubility threshold.
Type I/III cystinuria
DNA was available for analysis on 9 of the 12 Type I/III
probands. We were able to detect only one SLC3A1
mutation among the 9 alleles contributed by the Type I/N
parent (detection rate 11%; Table 2). This mutation
(M467T) corresponded to the most common cystinuria
allele reported in Spanish and Italian populations [7].
Average morning urinary cystine (ages 1 to 7 years)
among the Type I/III children was 1544 6 163 mmol
cystine/g creatinine, which was significantly lower (P ,
0.001, Student t-test) than for their Type I/I cystinuria
counterparts. However, for patients in both groups, there
Fig. 1. Urine cystine excretion by Type I/I cystinuria probands in relation
to the theoretic threshold of solubility. Urine cystine (mmol cystine/liter)
of individual morning urine samples between age 1 to 7 years is plotted
versus urine pH in relation to the theoretic threshold of cystine solubility.
Fig. 2. Urine cystine excretion by four Type I/I stone forming cystinuria
probands at various times of the day. Urine cystine (mmol cystine/liter) is
plotted versus urinary pH: 5 to 7 a.m. (f), 11 a.m. to 12 p.m. (X), 3 to
4 p.m. (F), and 8 to 10 p.m. () in relation to the theoretic threshold of
cystine solubility.
Table 1. Type I/I cystinuria
Patient Mutation Age
Age at
first stone
Urinary cystine excretion mmol cystine/g creatinine
Proband Mother Father
780-1 T216M/T216M 8 2 4795 58 42
(2765-4464)
782-1 974delGA/S217R 10 9 2578 80 26
(1915-3241)
782-2a 974delGA/S217R 8 — 5778 80 26
(2394-9163)
936-1a del/del 8 — 5778 69 40
(2394-9163)
1226-1 R270L/M467T 16 — 5361 24 1
(4157-6564)
817-1 150011G3T/del 31 6 2482c 26 31
(1674-3289)
818-1a E483X/P337P 8 — 4255 83 46
(3116-5392)
885-1 150011G3T/? 9 7 5500 33 42
(3665-7330)
1440-1b 1810delTG/1810delTG 30 ? — — —
a Author, please define or delete
b Please define
c Please define
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was considerable day-to-day variability and individual val-
ues often overlapped in the range of 2000-3000 mmol
cystine/g creatinine. Thus, probands could not readily be
classified as to cystinuria subtype without family studies or
molecular analyses.
When cystine concentration (mmol cystine/liter) in indi-
vidual morning urine samples was plotted as a function of
urinary pH, 22% of samples exceeded the theoretic limit of
cystine solubility (Fig. 3). Only one patient in this group has
formed a kidney stone (documented by renal ultrasonog-
raphy), and this was at age 16. Since the mean age of Type
I/III patients was younger than that of the Type I/I group,
we analyzed only the patients who had been followed for at
least eight years for comparison of nephrolithiasis risk in
the two groups. Five of nine Type I/I patients formed a
stone in the first decade whereas all eight Type I/III
patients were stone-free in this period (P , 0.03, two-tailed
Fisher’s exact test).
Type II/Normal cystinuria
Two patients who excreted .1000 mmol cystine/g creat-
inine at one year of age were classified as Type II/Normal
cystinuria, based on parental urinary phenotype (Table 3).
In each case, the level of urinary cystine excretion in the
proband was comparable to that of one parent. In the
1245-1 kindred, the proband’s maternal grandfather was
also affected (1741 mmol cystine/g creatinine) and had a
history of nephrolithiasis in adulthood. In the 918-1 kin-
dred, the proband’s affected father passed a stone at 36
years of age. No SLC3A1 mutations were identified in the
two Type II/Normal patients. No nephrolithiasis was noted
in the children, but the cystine concentration of morning
urine samples (age 1 to 7 years) has often exceeded its
theoretic solubility limit (Fig. 4).
DISCUSSION
Although three subtypes of cystinuria have been recog-
nized since 1968 [1], prospective studies comparing the
relative nephrolithiasis risk in each group have been diffi-
cult to accomplish. Most reports involve cohorts of patients
who first come to medical attention only once the first stone
Fig. 3. Urine cystine excretion by Type I/III cystinuria probands in
relation to the theoretic threshold of solubility. Urine cystine (mmol
cystine/liter) of individual morning urine samples between ages 1 to 7
years is plotted versus urine pH in relation to the theoretic threshold of
cystine solubility.
Table 2. Type I/III cystinuria
Patient Mutation Age
Age at
first stone
Urinary cystine excretion mmol cystine/g creatinine
Proband Mother Father
947-1 M467T/? 8 — 2178 53 235
(1541-2814)
872-1 ?/? 19 16 2714 306 29
(1900-3528)
732-1 ?/? 15 — 1624 417 45
(899-2347)
1390-1 ?/? 5 — 1267 78 402
(708-2087)
829-1 ?/? 12 — 1688 420 47
(1110-2266)
830-1 ?/? 11 — 1136 120 51
(848-1424)
979-1 ?/? 13 — 1239 165 70
(970-1507)
988-1 ?/? 8 — 1343 577 30
(290-2839)
1326-1 ?/? 6 — 892 22 212
(455-1330)
1500-1 ?/? 8 — 2210 124 34
(845-3575)
1501-1 ?/? 7 — 1352 250 36
(1117-1588)
1502-1 ?/? 6 — 885 35 394
(432-1337)
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is formed, which is often in adulthood when parental
studies are not always possible. Consequently, it is unclear
whether an appreciable number of cystinuria patients re-
main asymptomatic and whether the risk of nephrolithiasis
is primarily determined by the nature of the cystinuria
genes inherited or by other multifactorial determinants
(such as, urinary stone inhibitors or environmental condi-
tions). In this study, we have taken advantage of the
Quebec Genetic Network Neonatal Screening Program to
identify 22 cystinuria patients, classify them on the basis of
parental urinary phenotype and SLC3A1 gene status, and
collect longitudinal outcome data.
Our experience suggests that a “classic” form of cystin-
uria can be defined in infants excreting over 1000 mmol
cystine/g creatinine at one year of age in whom both
parents are completely “silent” carriers, excreting cystine in
the normal range (,100 mmol cystine/g creatinine). In
nearly all of these children, defective cystine excretion can
be attributed to two mutations of the SLC3A1 gene. Since
SLC3A1 expression has been shown to be highly restricted
to the straight (S3) segment of the proximal tubule [18, 19],
it is presumably the dysfunction of the shared cystine/
dibasic amino acid transporter in this nephron segment
which accounts for Type I/I cystinuria.
Our data show that the risk of nephrolithiasis in children
with the “classic” Type I/I form of cystinuria is quite high;
at least 50% will form one or more stones within the first
decade of life. It should be pointed out that the incidence
of early stone formation may be even greater, since three of
the Type I/I probands were placed on potassium citrate by
age 6 to 7 years. The nephrolithiasis risk may be attribut-
able to the especially high level of cystine excretion associ-
ated with a pair of SLC3A1 mutations. On the other hand,
this genetic burden can be modifed somewhat. The likeli-
hood of excreting cystine in the supersaturated range
appears to be greatest overnight when urine normally
becomes most concentrated and acidic. Traditional strate-
gies to dilute and alkalinize the urine might especially
target this time period. Plots of urine cystine versus pH
demonstrate that Type I/I patients are more likely to
exceed the solubility threshold than other groups, but it is
uncertain whether these plots are useful to anticipate
nephrolithiasis in the individual patient.
In a second form of cystinuria, probands are born of one
parent excreting cystine within the normal range and one
parent with moderately elevated cystine excretion. In one
of our patients, the “silent” (,100 mmol cystine/g creati-
nine) Type I/Normal heterozygous urinary phenotype was
associated with an SLC3A1 mutation, but in most, no
mutation was demonstrated. Linkage analysis has shown
that a gene mapping to an entirely different locus at
chromosome 19q13.1 accounts for Type III (and probably
Type II) cystinuria [13–15]. Although the molecular basis
for Type I/III cystinuria has not yet been unraveled, it is
clear that these patients have a somewhat milder form of
the disease. Thus far, none of our Type I/III patients have
formed a stone in the first decade of life, and at present we
advise only careful monitoring of urine cystine versus pH
and occasional ultrasonography for this group. However,
the risk of nephrolithiasis at later ages cannot be dis-
counted since many of our patients have not been followed
into adulthood. Stone formation has occurred in one
16-year-old Type I/III patient, and the cystine concentra-
tion exceeds the theoretic threshold of solubility in 22% of
random urine samples.
Two patients identified by the Quebec Network Neonatal
Screening program who excreted .1000 mmol cystine/g
creatinine at one year of age were classified as Type
II/Normal. In these families, cystinuria behaves as an
autosomal dominant phenotype since the same relatively
high range of urinary cystine was noted in two or three
Fig. 4. Urine cystine excretion by Type II/Normal cystinuria patients in
relation to the theoretic threshold of solubility. Urine cystine concentra-
tion (mmol cystine/liter) of individual morning urine samples between ages
1 to 7 years is plotted versus urine pH in relation to the theoretic threshold
of cystine solubility.
Table 3. Type II/Normal cystinuria
Patient Mutation Age
Age at
first stone
Urinary cystine excretion mmol cystine/g creatinine
Proband Mother Father
1245-1 ?/Normal 7 — 1777 1500 50
(1314-2239)
918-1 ?/Normal 17 — 894 44 843
(707-1080)
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generations. In both Type I/I and Type I/III families, the
risk of nephrolithiasis is recessive, since only the proband
excretes cystine in the supersaturated range. We were
unable to identify SLC3A1 mutations in either Type II/
Normal proband. Conceivably, these patients are heterozy-
gous for a more dysfunctional or dominant-negative muta-
tion at the 19q13.1 locus as suggested by the linkage studies
of Bisceglia et al [14]. Although our two probands have not
yet formed stones, urinary cystine occasionally exceeds the
theoretic solubility threshold and the family history in each
suggests that occasional stone formation may occur later in
life. Since Type II cystinuria is quite rare in our population,
the great majority of cystine stones will be formed in
patients with Type I/I or Type I/III cystinuria.
Although this study does not directly address therapy,
our observations suggest that patients with Type I/III or
Type II/Normal cystinuria might be managed during child-
hood by prescription of a high daily fluid intake alone, since
the risk of nephrolithiasis is low. However, for Type I/I
patients, it may be warranted to introduce standard antic-
ipatory therapies such as alkalinizing agents at age five to
six years, when the risk of stone formation appears to
increase. Studies are underway to determine whether neph-
rolithiasis can be anticipated in the individual patient by
monitoring early the morning urine cystine concentration
in relationship to its theoretical limit of solubility.
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